(CS-140) Treatment of Hard to Heal Acute and Chronic Wounds with AC5 Advanced Wound System

Co-Author(s):

Jessica Baker, RN – staff nurse, wound care, Institute for Advanced Wound Care; lyudmila Nikolaychook, MD – physician, wound care, Institute for Advanced Wound Care; angela Pickens, RN – staff nurse, wound care, Institute for Advanced Wound Care

Introduction:

When wounds do not respond to standard of care within 4 weeks of treatment, more advanced therapies are recommended. ^1,2  Utilizing a matrix scaffold to aid in cell adhesion, migration, multiplication and differentiation is one approach to this problem. ³  The AC5 Advanced Wound System is a synthetic self-assembling peptide scaffold which stimulates healing in hard to heal acute and chronic wounds. ⁴ The assembled peptide resembles a bioresorbable type I collagen matrix  similar to extracellular matrix.  It creates a wound barrier against contamination and modulates the inflammatory wound environment. ^5,6 It has been found to have hemostatic properties. ⁴

Methods: In an effort to analyze the efficacy of this therapy, we have treated 10 patients with hard to heal traumatic wounds, postoperative wounds, diabetic ulcers, and venous ulcers with AC5 for 8 weeks with 7 (70%) being treated weekly and 3 (30%) randomly selected to be treated every other week.  The average size of the treated wounds was 7.95 cm² with the largest being 32 cm².

Results:

Preliminary results indicated that 71% of patients treated weekly had a >50% reduction of wound area at 4 weeks while 33% of the patients treated every other week achieved that level of healing.  Final and complete results including healing rates will be presented. 

Discussion:

From the preliminary data, it appears that AC5 can be beneficial in the treatment of both acute and chronic hard to heal wounds.

Trademarked Items: AC5® Advanced Wound System, Arch Therapeutics, Inc., Framingham, MA

References: 1. Sheehan P, Jones P, Caselli A, et. al. Percent Change in Wound Area of Diabetic Foot Ulcers Over a 4-Week Period Is a Robust Predictor of Complete Healing in a 12-Week Prospective Trial. Diabetes Care 2003;26(6):1879-1882
2. Eriksson E, Liu P, Schultz G, et. al. Chronic Wounds: Treatment Consensus. Wound Rep Reg 2022;30:156-171
3. Ellis-Behnke RG, Laing Y, Guo J, et. al. Forever Young: How to Control the Elongation, Differentiation, and Proliferation of Cells Using Nanotechnology. Cell Transplantation 2009;18:1047-1058
4. Kapp D, Pfendler L, D’Oro l, Wolcottt R. Early Clinical Performance of an Adaptive Self-Assembling Barrier Scaffold in Nonhealing Chronic Wounds: A Review of Six Cases. Wounds 2022;34(1):20-30
5. Csukas D, Urvanics R, Moritz A, et. al. AC5 Surgical Hemostat TM as an Effective Hemostatic Agent in an Anticoagulated Rat Liver Punch Biopsy Model. Nanomedicine 2015;11(8):2025-2031
6. Kapp D, Norchi T. Healing of a Complex Surgical Wound Using a Novel Self-Assembling Peptide-Based Advanced Wound Dressing. Poster presented at: Symposium on Advanced Wound Care (SAWC) Fall; November 4-6,2020; Virtual